HIV-associated Lipodystrophy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Drug Treatment, Cosmetic Corrective Treatment), By Route of Administration (Oral, Injectables, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region and Competition 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 185.82 Million
CAGR (2026-2031)	3.52%
Fastest Growing Segment	Drug Treatment
Largest Market	North America
Market Size (2031)	USD 228.62 Million

Market Overview

The Global HIV-associated Lipodystrophy Market will grow from USD 185.82 Million in 2025 to USD 228.62 Million by 2031 at a 3.52% CAGR. HIV-associated lipodystrophy is defined as a metabolic syndrome characterized by abnormal fat redistribution, including lipoatrophy and lipohypertrophy, which frequently occurs as an adverse reaction to antiretroviral regimens. The primary drivers of this market include the sustained increase in the global HIV-positive population and the widespread scale-up of antiretroviral therapy (ART) programs, which have significantly prolonged patient life expectancy and subsequent exposure to long-term side effects. Additionally, the medical necessity to mitigate cardiovascular risks associated with metabolic irregularities supports the demand for effective management strategies, distinct from transient aesthetic trends.

Nevertheless, market growth is substantially hindered by the prohibitive costs of approved therapeutics and inadequate reimbursement policies, which limit widespread accessibility for patients in low-to-middle-income regions. This economic barrier poses a critical difficulty despite the expanding target demographic that requires continuous care. According to UNAIDS, at the end of 2024, approximately 31.6 million people globally were accessing antiretroviral therapy, indicating a substantial increase in the population potentially susceptible to developing treatment-related lipodystrophy.

Key Market Drivers

The Increasing Global Prevalence of HIV Infection serves as the foundational engine for market demand, as the expanding population of long-term survivors directly correlates with a higher incidence of metabolic complications. As antiretroviral therapies extend lifespans, patients are exposed to life-saving regimens for longer durations, thereby accumulating the risk of developing adverse fat redistribution syndromes such as lipoatrophy and lipohypertrophy. This growing patient base creates a sustained medical need for corrective interventions to manage these chronic side effects. According to UNAIDS, July 2024, in the 'Fact Sheet 2024', approximately 39.9 million people globally were living with HIV in 2023, representing a vast reservoir of patients potentially requiring lipodystrophy management. To further illustrate the scale of this chronic market, according to the Centers for Disease Control and Prevention, in 2024, an estimated 1.2 million people in the United States were living with diagnosed and undiagnosed HIV at the end of 2022, underscoring the substantial demand in high-value regional markets.

Advancements in Novel Therapeutic Agents and Dermal Fillers are significantly accelerating market revenue by transitioning treatment options from purely management-based approaches to effective aesthetic and metabolic restoration. The commercialization of targeted growth hormone-releasing factors and specialized volumizing fillers has incentivized treatment adoption among patients seeking to alleviate the stigmatizing physical changes associated with the condition. This segment is witnessing robust financial performance, validating the willingness of healthcare systems and patients to invest in these therapies. According to Theratechnologies Inc., October 2024, in the 'Q3 2024 Earnings Call Transcript', net sales of EGRIFTA SV, a targeted injectable for the reduction of excess abdominal fat in HIV-infected patients, reached USD 16.7 million in the third quarter alone. This uptake demonstrates that despite economic barriers, the availability of efficacious, approved products remains a potent driver of industry expansion.

Download Free Sample Report

Key Market Challenges

The prohibitive costs of approved therapeutics and inadequate reimbursement policies act as a primary restraint on the growth of the Global HIV-associated Lipodystrophy Market. This economic barrier creates a significant disconnect between the clinical need for treatment and the actual purchasing power of the affected demographic. Since lipodystrophy management is often categorized as a secondary intervention compared to life-saving antiretroviral therapy, insurance coverage remains limited or non-existent in many jurisdictions. Consequently, manufacturers face difficulties in penetrating low-to-middle-income regions where healthcare budgets are strictly allocated to essential viral suppression, preventing the widespread adoption of approved drugs despite their clinical efficacy.

This financial limitation is especially critical given the sheer scale of the global patient population that requires long-term management. The market opportunity is theoretically vast but practically constricted by affordability issues in high-burden areas, effectively placing a ceiling on revenue generation. According to UNAIDS, in 2024, there were approximately 40.8 million people living with HIV globally. This extensive patient base represents a substantial unmet need, yet the market cannot fully leverage this demand as long as high out-of-pocket expenses and reimbursement gaps render treatments inaccessible for the majority of individuals living with the condition.

Key Market Trends

The Commercialization of Advanced Growth Hormone-Releasing Factor Formulations is reshaping the market landscape by prioritizing patient adherence through enhanced delivery mechanisms. While earlier therapeutic options established clinical efficacy, the industry is now pivoting towards next-generation, user-friendly formulations that significantly reduce the logistical burden of daily administration for long-term survivors. This evolution addresses the critical issue of "treatment fatigue" in chronic HIV care, ensuring sustained therapeutic outcomes by simplifying complex regimens. According to Theratechnologies Inc., March 2025, in the 'First Quarter 2025 Financial Results', the U.S. FDA approved EGRIFTA WR, a new F8 formulation of tesamorelin specifically designed to treat excess visceral abdominal fat, marking a pivotal advancement in optimizing the long-term metabolic management for this patient population.

Simultaneously, the Rising Adoption of Minimally Invasive Dermal Fillers is being fueled by the specific surge in regenerative biostimulators that offer durable structural restoration beyond transient volume correction. Unlike traditional hyaluronic acid options, agents such as poly-L-lactic acid are gaining substantial market share by stimulating the host's collagen production, thereby providing a more permanent physiological solution to facial lipoatrophy. This sub-segment has evolved into a critical revenue generator for major aesthetic portfolios, validating the commercial shift towards regenerative medicine. According to Galderma Group AG, March 2025, in the 'Annual Report 2024', the company delivered record net sales of USD 4.41 billion, with its flagship biostimulator brand Sculptra serving as a primary driver of growth within the injectable aesthetics category.

Segmental Insights

The Drug Treatment segment serves as the fastest-growing category within the Global HIV-associated Lipodystrophy Market, primarily driven by the introduction of targeted pharmaceutical therapies. This rapid expansion results from favorable decisions by regulatory bodies, such as the U.S. Food and Drug Administration, which have approved specific medications for reducing excess abdominal fat. Healthcare providers are increasingly favoring these medicinal approaches over traditional surgical methods because they address underlying metabolic issues rather than only physical appearance. This transition toward pharmaceutical management ensures a consistent demand for drug-based solutions, establishing them as the primary driver of current market progress.

Regional Insights

North America maintains a leading position in the Global HIV-associated Lipodystrophy Market due to the high prevalence of diagnosed HIV cases and the extensive utilization of long-term antiretroviral therapies. This dominance is supported by established healthcare systems and favorable reimbursement frameworks that facilitate patient access to specialized treatments. Furthermore, the active involvement of major pharmaceutical companies and the approval of specific therapeutic agents by the US Food and Drug Administration drive regional growth. Increased clinical awareness regarding the metabolic side effects of HIV management continues to strengthen the market significantly within this region.

Recent Developments

• In September 2025, Theratechnologies officially announced the commercial availability of Egrifta WR in the United States, marking the market launch of its upgraded treatment for HIV-associated lipodystrophy. This new product was positioned to replace the older Egrifta SV formulation, leveraging a simplified dosing structure to better serve the needs of the patient community. The launch was supported by a partnership with a U.S.-based contract manufacturing organization, ensuring a robust supply chain for the therapy. This development represented a strategic consolidation of the company's portfolio within the Global HIV-associated Lipodystrophy Market, focusing on enhanced product attributes and long-term commercial sustainability.
• In March 2025, Theratechnologies obtained approval from the U.S. Food and Drug Administration for Egrifta WR, a novel formulation of tesamorelin previously referred to as the F8 formulation. This regulatory milestone introduced a significant product evolution in the Global HIV-associated Lipodystrophy Market, offering patients a more convenient once-weekly reconstitution regimen compared to the daily preparation required by its predecessor. The company highlighted that this approval aligned with its strategy to improve treatment adherence and patient quality of life by simplifying the administration of therapies for managing visceral abdominal fat in adults living with HIV.
• In December 2024, Theratechnologies announced the resumption of production for Egrifta SV, a key therapeutic in the Global HIV-associated Lipodystrophy Market, following a voluntary shutdown of its contract manufacturer's facility. This temporary pause had been initiated to resolve observations made by the U.S. FDA during a prior inspection of the manufacturing site. The company confirmed that a newly manufactured batch had successfully completed quality control protocols and was awaiting regulatory clearance for release. This operational recovery was crucial for maintaining a stable supply of the only FDA-approved treatment for HIV-associated lipodystrophy and mitigating potential stockouts for patients.
• In January 2024, Theratechnologies received a Complete Response Letter from the U.S. Food and Drug Administration regarding its supplemental Biologics License Application for the F8 formulation of tesamorelin. The regulatory agency raised specific questions concerning chemistry, manufacturing, and controls, focusing on the microbiology, assays, impurities, and stability of the lyophilized product intended for the Global HIV-associated Lipodystrophy Market. Additionally, the FDA requested further data to assess the potential immunogenicity risk of this concentrated formulation. The company committed to addressing these observations to advance the development of this simplified dosing option for reducing excess abdominal fat in HIV patients.

Key Market Players

• Theratechnologies Inc
• Amryt Pharmaceuticals, Inc.
• Fawn Incorporation
• Abbott Laboratories, Inc.
• Lupin Pharmaceuticals, Inc.
• Pfizer Inc.
• Bayer AG
• Novartis Pharmaceuticals Corporation
• AstraZeneca Plc
• GlaxoSmithKline Plc

By Type	By Route of Administration	By Distribution Channel	By Region
Drug Treatment Cosmetic Corrective Treatment	Oral Injectables Others	Hospital Pharmacies Retail Pharmacies Online Pharmacies	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global HIV-associated Lipodystrophy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• HIV-associated Lipodystrophy Market, By Type:

• Drug Treatment
• Cosmetic Corrective Treatment

• HIV-associated Lipodystrophy Market, By Route of Administration:

• Oral
• Injectables
• Others

• HIV-associated Lipodystrophy Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

• HIV-associated Lipodystrophy Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE